Shares of TrovaGene Inc. (Nasdaq: TROV) soared nearly 16% Wednesday after the investors shrugged off a first-quarter earnings miss and focused on the impressive progress the San Diego-based company is making with its "liquid biopsy" technology.
We first recommended TrovaGene back on March 11. With yesterday's surge, folks who acted on our original call now have a 56% profit in this development-stage biotech stock in just under two months.
While the earnings report had a happy ending, it didn't have a happy beginning. When the results were released Tuesday, investors were chagrined. On Tuesday, TrovaGene said revenue surged 14.4% to $127,000 in the fiscal first quarter.
This is premium content for Private Briefing subscribers only.